Photo of Ravindra Uppaluri,  MD, PhD

Ravindra Uppaluri, MD, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-3643

Ravindra Uppaluri, MD, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Associate Professor, Surgery, Harvard Medical School
  • Director, Head and Neck Surgical Oncology, Medical Oncology, Dana-Farber Cancer Institute
  • Director, Head and Neck Surgical Oncology, Surgery, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

I have dedicated my career to the care of patients with head and neck cancers and developed a basic and translational research program focused on biology and therapeutic approaches of head and neck squamous cell carcinomas. My research program focuses on the development and study of high-fidelity models of oral squamous cell carcinoma and translational applications of findings therein. A major effort in the laboratory has focused on molecular determinants of aggressiveness in oral squamous cell carcinomas (OSCC) that has lead to identification of (1) novel molecular signature that allow patient outcomes stratification (2) previously unexplored pathways in tumor cell aggressive growth and metastasis and (3) direct translational efforts in patients with oral cancer. I am the Principal Investigator of one recently completed and one active clinical trial treating patients with head and neck squamous cell carcinoma. The recently completed trial utilized the MEK inhibitor trametinib in a window of opportunity biomarker clinical trial. The current open trial is aimed at treatment intensification with pembrolizumab, an anti-PD-1 blocking monoclonal antibody, in high-risk head and neck cancer patients. My recent move to the Dana-Farber and Brigham and Women’s Cancer Center as Director of Head and Neck Surgical Oncology has positioned me in an ideal milieu for our continued work on the genomic basis of tumor aggressiveness using the spectrum of laboratory modeling to patient samples. This work is complemented by my role as a surgeon in the multidisciplinary management of patients with head and neck cancer.

Publications

Powered by Harvard Catalyst
  • Schoenfeld JD, Gjini E, Rodig SJ, Tishler RB, Rawal B, Catalano PJ, Uppaluri R, Haddad RI, Hanna GJ, Chau NG, Rabinowits G, Lorch J, Jo VY, Krane JF, Goguen LA, Annino DJ, Abdelrahman S, Lipschitz M, Margalit DN. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2018. PubMed
  • Hanna GJ, Kofman ER, Shazib MA, Woo SB, Reardon B, Treister NS, Haddad RI, Cutler CS, Antin JH, Van Allen EM, Uppaluri R, Soiffer RJ. Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. Oral Oncol 2018; 81:1-9. PubMed
  • Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, Chau NG, Schoenfeld JD, Lorch JH, Uppaluri R, MacConaill LE, Haddad RI. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight 2018. PubMed
  • Chung MK, Jung YH, Lee JK, Cho SY, Murillo-Sauca O, Uppaluri R, Shin JH, Sunwoo JB. CD271 Confers an Invasive and Metastatic Phenotype of Head and Neck Squamous Cell Carcinoma through the Upregulation of Slug. Clin Cancer Res 2018; 24:674-683. PubMed
  • Zolkind P, Przybylski D, Marjanovic N, Nguyen L, Lin T, Johanns T, Alexandrov A, Zhou L, Allen CT, Miceli AP, Schreiber RD, Artyomov M, Dunn GP, Uppaluri R. Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. 2018; 9:4109-4119. PubMed
  • Redlich N, Robinson AM, Nickel KP, Stein AP, Wheeler DL, Adkins DR, Uppaluri R, Kimple RJ, Van Tine BA, Michel LS. Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma. Cell Death Dis 2018; 9:5. PubMed
  • Hanna GJ, Adkins DR, Zolkind P, Uppaluri R. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. Oral Oncol 2017; 73:65-69. PubMed
  • Zolkind P, Uppaluri R. Checkpoint immunotherapy in head and neck cancers. Cancer Metastasis Rev 2018; 36:475-489. PubMed
  • Zolkind P, Dunn GP, Lin T, Griffith M, Griffith OL, Uppaluri R. Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. Oral Oncol 2018; 71:169-176. PubMed
  • Uppaluri R, Winkler AE, Lin T, Law JH, Haughey BH, Nussenbaum B, Paniello RC, Rich JT, Diaz JA, Michel LP, Wildes T, Dunn GP, Zolkind P, Kallogjeri D, Piccirillo JF, Dehdashti F, Siegel BA, Chernock RD, Lewis JS, Adkins DR. Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial. Clin Cancer Res 2018; 23:2186-2194. PubMed
  • Ravindra Uppaluri, Ashley E. Winkler, Tianxiang Lin, Jonathan H Law, Bruce H Haughey, Brian Nussenbaum, Randal C Paniello, Jason T Rich, Jason A Diaz, Loren S Michel, Tanya Wildes, Gavin P. Dunn, Paul Zolkind, Dorina Kallogjeri, Jay F Piccirillo, Farrokh Dehdashti, Barry A. Siegel, Rebecca D. Chernock, James S Lewis and Douglas R Adkins. Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window of Opportunity Clinical Trial Clin Cancer Res 2016.